News from endocrine treatment in breast cancer from the San Antonio Breast Cancer Symposium 2008
Endocrine treatment in combination with signal transduction inhibitors was a major concern of this year’s San Antonio Breast Cancer Symposium. Johnston gave the first plenary lecture on how to overcome endocrine resistance. He presented the first results of the EGF30008 trial: Lapatinib in combination with letrozole. The efficacy of aromatase inhibitors compared with tamoxifen for the treatment of hormone receptor-positive breast cancer has been the subject of numerous large-scale clinical trials. Henning Mouridsen from Denmark presented new results from the BIG-1-98 trial. Raimund Jakesz and M Goetz on behalf of the ABCSG presented the results of the ABCSG trials 8 and the pharmacogenetic and gene expression profiles and molecular grade index for the prediction of endocrine therapy.